- In the field of regenerative medicine using iPS Cell, where Japan is at the forefront, Megakaryon is the leading start-up closest to world-wide commercialization
- Artificially produced platelet preparations can overcome supply constraints and the risk of viral infection associated with dependence on donated blood
Our Portfolio
Megakaryon Corporation
Outline | Development of platelet preparations using human induced pluripotent stem (hiPS) cells (It (1) can produce a stable supply of platelets, (2) has a high safety profile and (3) makes low-medical-cost blood transfusions possible) |
---|---|
Website | |
Industry | Health/medicine |
Commercialization stage | Early stage |
Provided Support
Authorized Investment | ¥1 billion (maximum) / ¥2 billion (maximum) / ¥1.1 billion (maximum) |
---|---|
Announcement Date | Aug 26, 2013 / Mar 23, 2015 / Dec 25, 2017 |
Investment Structure |
Related Press Releases
- Dec 25, 2017
- INCJ to make additional investment in Megakaryon Corporation
- Mar 23, 2015
- INCJ to make additional investment in Megakaryon